|
NIAID/FDA/BARDA Meeting on Gastrointestinal Acute Radiation Syndrome (GI-ARS)
|
Meeting/ Workshop
|
FDA, ASPR
|
NIAID
|
The purpose of this meeting is to bring together medical countermeasures stakeholders such as academicians, industry, and funding and regulatory agencies to consider animal models and endpoints for radiation injuries to the gastrointestinal tract.
|
|
NIAID/FDA/BARDA Meeting on Radiation-Induced Lung Injuries
|
Meeting/ Workshop
|
FDA, ASPR
|
NIAID
|
A meeting was held March 20-21, 2019. The purpose of this meeting was to bring together medical countermeasures stakeholders such as academicians, industry, and funding and regulatory agencies to consider animal models and endpoints for radiation injuries to the lung. Both a meeting report and commentary were peer-reviewed and published in 2021.
|
|
NIAID/NASA Medical Countermeasures Working Group
|
Committee, Work group, Advisory group, or Task Force
|
BARDA, FDA
|
NIAID, NCI, NHLBI
|
The purpose of this Working Group (WG) is to bring together experts in radiation countermeasures to look for complementary areas of research across agencies in the following areas: medical countermeasure selection, repurposing, research strategies, and animal models for select endpoints.
|
|
Nicotine Research Cigarettes (SPECTRUM)
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIDA
|
This partnership with the Food and Drug Administration (FDA) is for the production of research cigarettes.
|
|
NIDA-FDA Interagency Clinical Outcomes Assessment Working Group (ICOAWG)
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIDA, NCI, OD/DPCPSI/OBSSR
|
The Interagency Clinical Outcomes Assessment Working Group (ICOAWG) facilitates scientific exchange between the National Institutes of Health (NIH) and Federal Drug Administration (FDA) and helps to guide research and stay abreast of new and ongoing clinical trials and measurement approaches being used. There is a focus on standards and use of Clinical Outcome Assessments.
|
|
NIEHS SBIR PHASE IIB Awards for Validation and Commericialization of Approaches to Reduce Animal Use in Toxicology Testing (U44)
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIEHS
|
This SBIR program uses a cooperative agreeement mechanism, including regular consulation with a Steering Committee (SC), to conduct formal validation of alternative test methods. The SCs consist of ICCVAM NICEATM members.
|
|
NIH Autoimmune Diseases Coordinating Committee (ADCC)
|
Committee, Work group, Advisory group, or Task Force
|
FDA, HRSA
|
NIEHS, NIAID, OD, NCI, NCATS, NCCIH, NEI, NHLBI, NHGRI, NIAMS, NIBIB
|
The purpose of the ADCC is to facilitate coordination of research across the National Institutes of Health (NIH), federal agencies, professional societies, and patient and advocacy organizations with an interest in autoimmune diseases. The ADCC meets once or twice yearly.
|
|
NIH Common Data Elements Task Force (CDETF)
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, FDA, CMS, ASPE, CDC
|
NLM, CC, CIT, CSR, FIC, NCATS, NCCIH, NCI, NCMHD, NCRR, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NINDS, NINR, OD/DPCPSI/OBSSR, OD/DPCPSI/ODSS, OD/OER, OD/AoU, OD/DPCPSI/ODP, OD/DPCPSI/ORWH, OD/DPCPSI/SGMRO, OD/ECHO, NIGMS, NIMH, NIMHD
|
The NIH CDE Task Force as a whole provides a trans-NIH communications forum – including COVID-related activities. Through its subgroups, such as the COVID CDE Coordinating Committee and the NIH CDE Governance Committee, the Task Force addresses specific trans-NIH issues like coordination across COVID efforts, NIH CDE governance, etc.
|
|
NIH COVID-19 Treatment Guidelines Panel
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
NIAID
|
The Panel was formed in March 2020, at the beginning of the COVID-19 pandemic in the US. The Panel includes members from academia and professional societies. Five USG ex-officio members are on the Panel, including representatives from BARDA, CDC, DoD, FDA, and VA. The Panel is responsible for writing and updating guidelines for the treatment of COVID-19
|
|
NIH Guide for Grants and Contracts
|
Resource Development
|
AHRQ, CDC, FDA
|
OD/OER, CC, CIT, CSR, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI
|
The National Institutes of Health (NIH) Guide for Grants and Contracts is the official publication for NIH medical and behavioral grant policies, guidelines, and funding opportunities. Other US Department of Health and Human Services agencies also use the Guide to disseminate Funding Opportunity Announcements to its 60,000 subscribers.
|